04.06.2018
MorphoSys AG DE0006632003
DGAP-News: MorphoSys to Present at Upcoming Investor Conferences
DGAP-News: MorphoSys AG / Key word(s): Conference
MorphoSys to Present at Upcoming Investor Conferences
04.06.2018 / 14:30
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Planegg/Munich, Germany, June 4, 2018
MorphoSys to Present at Upcoming Investor Conferences
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; NASDAQ: MOR) will
present at the following conferences:
dbAccess Berlin
Date: June, 6, 2018
Venue: Berlin, Germany
Presenter: Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG
Dr. Verena Kupas, Manager Corporate Communications & IR
JMP Securities Life Sciences Conference
Date: June 20, 2018
Venue: New York, NY, USA
Presenter: Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG
Dr. Verena Kupas, Manager Corporate Communications & IR
J.P. Morgan European Healthcare Conference
Date: June 21, 2018
Venue: London, UK
Presenter: Dr. Claudia Gutjahr-Löser, Investor Relations Officer
PDF versions of the presentations will be provided at www.morphosys.com. The
link to the webcasts will be filed under www.morphosys.com/conference-calls.
MorphoSys is a late-stage, biopharmaceutical company devoted to the
development of innovative and differentiated therapies for patients
suffering from serious diseases. Based on its technological leadership in
generating antibodies, MorphoSys, together with its partners, has developed
and contributed to the development of more than 100 product candidates, of
which 28 are currently in clinical development. This broad pipeline spans
MorphoSys's two business segments: Proprietary Development, in which the
Company invests in product candidates for its own account, and Partnered
Discovery, in which product candidates are developed exclusively for a
variety of Pharma and Biotech partners. In 2017, Tremfya(R) (guselkumab),
marketed by Janssen, became the first therapeutic antibody based on
MorphoSys's proprietary technology to receive marketing approval for the
treatment of moderate to severe plaque psoriasis in the United States, the
European Union and Canada. MorphoSys is listed on the Frankfurt Stock
Exchange and on the U.S. stock exchange Nasdaq, under the symbol MOR. For
regular updates about MorphoSys, visit http://www.morphosys.com.
HuCAL(R), HuCAL GOLD(R), HuCAL PLATINUM(R), CysDisplay(R), RapMAT(R),
arYla(R),
Ylanthia(R), 100 billion high potentials(R), Slonomics(R), Lanthio Pharma(R)
and LanthioPep(R) are registered trademarks of the MorphoSys Group.
Tremfya(R)
is a trademark of Janssen Biotech, Inc.
MorphoSys forward looking statements
This communication contains certain forward-looking statements concerning
the MorphoSys group of companies, the development of commercial
capabilities, in particular with respect to MOR208, and the transition of
MorphoSys to a fully integrated biopharmaceutical company, the expected time
of launch of MOR208, interaction with regulators, including the potential
approval of MorphoSys' current or future drug candidates, including
discussions with the FDA regarding the potential approval to market MOR208,
and expected royalty and milestone payments in connection with MorphoSys's
collaborations. The forward-looking statements contained herein represent
the judgment of MorphoSys as of the date of this release and involve known
and unknown risks and uncertainties, which might cause the actual results,
financial condition and liquidity, performance or achievements of MorphoSys,
or industry results, to be materially different from any historic or future
results, financial conditions and liquidity, performance or achievements
expressed or implied by such forward-looking statements. In addition, even
if MorphoSys' results, performance, financial condition and liquidity, and
the development of the industry in which it operates are consistent with
such forward-looking statements, they may not be predictive of results or
developments in future periods. Among the factors that may result in
differences are that MorphoSys' expectations regarding its 2018 results of
operations may be incorrect, MorphoSys' expectations regarding its
development programs may be incorrect, the inherent uncertainties associated
with competitive developments, clinical trial and product development
activities and regulatory approval requirements (including that MorphoSys
may fail to obtain regulatory approval for MOR208 and that data from
MorphoSys' ongoing clinical research programs may not support registration
or further development of its product candidates due to safety, efficacy or
other reasons), MorphoSys' reliance on collaborations with third parties,
estimating the commercial potential of its development programs and other
risks indicated in the risk factors included in MorphoSys's Registration
Statement on Form F-1 and other filings with the US Securities and Exchange
Commission. Given these uncertainties, the reader is advised not to place
any undue reliance on such forward-looking statements. These forward-looking
statements speak only as of the date of publication of this document.
MorphoSys expressly disclaims any obligation to update any such
forward-looking statements in this document to reflect any change in its
expectations with regard thereto or any change in events, conditions or
circumstances on which any such statement is based or that may affect the
likelihood that actual results will differ from those set forth in the
forward-looking statements, unless specifically required by law or
regulation.
For more information, please contact:
MorphoSys AG
Alexandra Goller
Associate Director Corporate Communications & IR
Jochen Orlowski
Associate Director Corporate Communications & IR
Dr. Claudia Gutjahr-Löser
Investor Relations Officer
Tel: +49 (0) 89 / 899 27-404
[email protected]
---------------------------------------------------------------------------
04.06.2018 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: MorphoSys AG
Semmelweisstr. 7
82152 Planegg
Germany
Phone: +49 (0)89 899 27-0
Fax: +49 (0)89 899 27-222
E-mail: [email protected]
Internet: www.morphosys.com
ISIN: DE0006632003
WKN: 663200
Indices: TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
692039 04.06.2018
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
MorphoSys AG ISIN: DE0006632003 können Sie bei EQS abrufen
Biotechnologie , 663200 , MOR , XETR:MOR